CONNECT WITH US
HealthTech

HealthTech

M&A: XRHealth Acquires PursueCare to Bridge Immersive VR Therapy with FDA-Authorized Prescription Digital Therapeutics

HIT Consultant logo

Published on

Add as a preferred source on Google
M&A: XRHealth Acquires PursueCare to Bridge Immersive VR Therapy with FDA-Authorized Prescription Digital Therapeutics

Therapeutic technology and immersive virtual healthcare platform XRHealth announced the strategic acquisition of PursueCare , a virtual behavioral health provider specializing in personalized addiction treatment for alcohol, opioids, cannabis, kratom, 7-OH, and co-occurring mental health conditions.

The transaction includes PursueCare’s comprehensive multidisciplinary telehealth clinics alongside its two landmark, FDA-authorized prescription digital therapeutics (PDTs): RESET® and RESET-O®.

The acquisition addresses a national public health crisis documented by SAMHSA: in 2025, 44.6 million Americans aged 12 or older had a substance use disorder (SUD), yet 89% received no substance use treatment, constrained by severe clinician shortages, rural provider deserts, societal stigma, and financial hurdles.

The combined clinical entity bridges PursueCare’s licensed addiction physicians, psychiatric clinicians, therapists, and case managers directly into XRHealth’s spatial computing ecosystem—spanning AR/VR headsets, smartwatches, smartphones, and connected home digital devices.

The integration brings together two historically distinct paradigms within digital therapeutics and behavioral telehealth into a unified care delivery model:

Multidisciplinary Telehealth & Medication-Assisted Treatment (MAT): PursueCare delivers comprehensive virtual outpatient care for alcohol, opioids, cannabis, and emerging novel substances such as kratom and 7-hydroxymitragynine (7-OH), alongside co-occurring psychiatric conditions. Its clinical model integrates medical evaluations, evidence-based pharmacotherapy—such as transmucosal buprenorphine for opioid use disorder (OUD)—psychiatric medication management, licensed therapy, and dedicated case management navigating social determinants of health (SDOH) like housing, transportation, and judicial re-entry.

S. FDA to deliver structured, software-driven cognitive behavioral therapy (CBT) and contingency management. RESET® is indicated over a 12-week (90-day) course to increase abstinence and program retention in adult outpatient SUD populations, while RESET-O® provides an 84-day adjunct CBT regimen alongside buprenorphine to drive outpatient retention in adult OUD.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.